Elfabrio (pegunigalsidase alfa-iwxj) for a UAE adult with Fabry disease: what the pathway looks like in 2026

*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.

A UAE-resident adult with Fabry disease walks into the conversation about Elfabrio with more than a treatment question. There is a diagnostic question, because Fabry diagnosis rests on an enzyme assay and GLA gene sequencing and the workup is not always complete by the time the patient is referred. There is a choice question, because Elfabrio is one of three commercial enzyme replacement therapies for Fabry disease and an oral pharmacological chaperone (migalastat) exists for patients whose GLA variant is amenable. There is a regulatory question, because Elfabrio received FDA approval in May 2023 and is recent enough that the named-patient pathway through the Emirates Drug Establishment is the realistic operational route in many UAE cases in 2026 even where Chiesi has commercial presence in the GCC. There is a family question, because Fabry is X-linked and the first-degree relative cascade testing conversation is always part of the picture. And there is a financial question, because chronic ERT is one of the most expensive long-term therapies on the market.

This page is meant to be the first honest read you get on Elfabrio in the UAE, written by the team that would coordinate around your treatment plan if you decided you wanted operational support on the diagnostic workup, the choice among the three ERTs, the EDE filing, the infusion centre, the antibody monitoring, and the long-term cost picture.

We will be specific about what Fabry disease is, what the diagnostic prerequisites are, where Elfabrio sits among the alternatives, what the UAE regulatory pathway looks like in 2026, what it costs in AED and US dollars, where the every-2-week infusions can be given in the UAE, what to monitor, and what life looks like settling into chronic ERT.

What Fabry disease is, in plain terms

Fabry disease is an X-linked lysosomal storage disorder. The GLA gene normally produces an enzyme called alpha-galactosidase A, which lives inside lysosomes and breaks down a long-chain fatty molecule called globotriaosylceramide, abbreviated Gb3. When GLA is faulty, Gb3 and related glycosphingolipids accumulate in lysosomes across the body, particularly in vascular endothelium, kidney podocytes, cardiomyocytes, and dorsal root ganglia neurons. The accumulation is what causes the disease.

Classic Fabry presents in childhood with burning pain in the hands and feet, intolerance of heat and cold, reduced sweating, gastrointestinal pain, and the characteristic small skin lesions called angiokeratomas. Renal failure, hypertrophic cardiomyopathy, and cerebrovascular events emerge in adulthood. Untreated life expectancy in classic Fabry males is reduced by approximately 20 years.

Later-onset and variant phenotypes present in middle adulthood with predominantly cardiac or predominantly renal involvement, sometimes without the classic childhood symptoms. These patients are often diagnosed during the workup for unexplained left ventricular hypertrophy or unexplained chronic kidney disease.

Female heterozygotes (carriers in classical Mendelian terminology, but the term is misleading) span the spectrum from asymptomatic to severely affected because of X-inactivation patterns. Many female Fabry patients have significant disease, often under-recognised, and benefit from ERT.

The X-linked inheritance pattern means mothers can transmit to sons and daughters. Fathers transmit to all daughters and to no sons. Once a Fabry diagnosis is confirmed in one family member, cascade testing of first-degree relatives is part of standard care. Many UAE Fabry families arrive at Reserve Meds with a known affected relative.

The diagnostic prerequisite that has to be in place

You cannot start Elfabrio without confirmed Fabry disease. The workup has two prongs and both must be in place:

Enzyme assay. Alpha-galactosidase A activity measured in leukocytes or via dried blood spot. In classic-Fabry males, enzyme activity is low or absent and the assay is diagnostic. In female heterozygotes, enzyme activity is often normal because of X-inactivation patterns; the enzyme assay alone cannot rule out Fabry in females.

GLA gene sequencing. Identifies the pathogenic variant. Confirmatory in males; primary diagnostic tool in females. Also informs the migalastat question: roughly 35 to 50 percent of GLA variants are amenable to the oral pharmacological chaperone, and amenability testing should be done before assuming ERT is the only option.

Supporting biomarkers include plasma or urine lyso-Gb3, which is elevated in Fabry and provides a baseline for treatment monitoring.

Baseline organ assessments at diagnosis: echocardiogram with strain imaging (LV mass, septal thickness, conduction system), cardiac MRI where available (myocardial fibrosis on T1 mapping is increasingly the standard cardiac assessment in Fabry), eGFR, albuminuria, urine protein/creatinine ratio, audiology, ophthalmology (cornea verticillata is a Fabry-specific finding), neurological screen including small fibre neuropathy assessment, and brain MRI for white matter lesions and silent infarcts.

The UAE-based reference laboratories used by SKMC, SSMC, Tawam, and Dubai Hospital can run the enzyme assay and gene sequencing on UAE soil; for amenability testing the standard is to send the genotype to one of the international Fabry reference laboratories. Where a patient arrives at Reserve Meds with the genetic confirmation but without the enzyme assay, or with the enzyme assay but without sequencing, we route the missing piece before the ERT conversation begins.

A clinical rationale letter from your treating geneticist or metabolic specialist documents the diagnosis (enzyme plus genetic), the amenability status for migalastat, the baseline organ-involvement picture, the recommended ERT choice and the reasoning, and the long-term monitoring schedule.

Where Elfabrio sits among the alternatives

Elfabrio is the third commercial enzyme replacement therapy for Fabry disease. The decision of which therapy to use is the treating geneticist's, based on patient-specific factors. We are not in the business of telling you which one is right. We will be specific about what is on the menu:

Agalsidase alfa (Replagal, Takeda): 0.2 mg/kg every 2 weeks, intravenous, approximately 40 minute infusion duration, CHO-cell-derived. Not FDA approved (available in the EU and in MENA). Generally lower infusion-reaction rate historically. Lower mg/kg dose may matter for high-substrate-burden patients.

Agalsidase beta (Fabrazyme, Sanofi): 1 mg/kg every 2 weeks, intravenous, CHO-cell-derived. FDA and EMA approved. Long track record. Anti-drug antibody development is common and is one of the reasons a geneticist may consider switching a patient to Elfabrio.

Elfabrio (pegunigalsidase alfa-iwxj, Chiesi/Protalix): 1 mg/kg every 2 weeks, intravenous, plant-cell-expressed in tobacco cell culture and chemically modified with PEG. FDA approved May 2023 (adults). EMA approved May 2023 (age 8 and older). The PEGylation is intended to extend plasma half-life and reduce immunogenicity.

Migalastat (Galafold, Amicus): oral pharmacological chaperone, one 123 mg capsule every other day. Indicated for adults with an amenable GLA mutation. Roughly 35 to 50 percent of Fabry mutations are amenable. Where amenable, migalastat is the alternative to lifelong every-2-week IV ERT entirely. Amenability is determined by genotype; the treating geneticist makes the call.

The clinical literature does not establish one ERT as superior to the others in head-to-head terms. The BALANCE trial showed non-inferiority of Elfabrio to agalsidase beta on the primary renal endpoint (annualised eGFR slope) over 24 months. The BRIDGE trial showed stable or improved renal function in patients switching from Replagal to Elfabrio over 12 months. The choice in any given patient is a clinical judgement that takes into account antibody status, infusion-reaction history, prior response, family preference, and local availability.

The UAE regulatory pathway: how it actually works in 2026

The Emirates Drug Establishment, which absorbed 44 of the Ministry of Health and Prevention's regulatory functions by early 2026, is the federal authority that the treating hospital files through. Elfabrio's UAE EDE registration status is in flux as of 2026; Chiesi has commercial presence in the GCC through regional distribution partners and where formal local registration is in place, standard prescription and import procurement applies. Where not, the named-patient mechanism is filed via ede.gov.ae by the hospital's import pharmacy on the treating geneticist or metabolic specialist's behalf. The Department of Health Abu Dhabi or Dubai Health Authority adds the emirate-level layer depending on where the infusions are given.

In our experience coordinating recent-FDA-approval rare-disease ERTs in the UAE, EDE coordination on a complete, well-documented file runs three to six weeks from filing to approval. For Elfabrio specifically, the variables that move the timeline are antibody status documentation (if switching from Fabrazyme or Replagal), the multidisciplinary picture (cardiac and renal staging), and the prior-treatment evidence packet.

The realistic UAE infrastructure for adult Fabry disease ERT: - Sheikh Khalifa Medical City, Abu Dhabi. Center for Genetic Diseases, adult internal medicine and metabolic team, infusion suite with anaphylaxis management. The UAE-side anchor for adult Fabry. - Sheikh Shakhbout Medical City, Abu Dhabi. Rare-disease infrastructure including ERT delivery. Genetic medicine service and adult cardiology depth. - Cleveland Clinic Abu Dhabi. Adult internal medicine, cardiology institute (cardiomyopathy programme is well-suited to the Fabry cardiac phenotype), nephrology, rare-disease pathway. - Tawam Hospital, Al Ain. Genetics service and metabolic infrastructure; can coordinate adult Fabry alongside the longstanding paediatric MPS programme. - Burjeel Medical City, Abu Dhabi. Metabolic clinic and infusion-suite capability. - Dubai Hospital. Dubai Genetic Diseases Programme; can coordinate Fabry workup and refer for ERT delivery. - Mediclinic City Hospital, Dubai. Cardiology depth relevant to Fabry cardiac phenotype; infusion-suite capability. - American Hospital Dubai. Adult internal medicine and infusion-suite capability for Dubai-side patients.

For UAE patients who need the deepest LSD programme in the region, KFSHRC Riyadh is the cross-border default. Reserve Meds coordinates the cross-border pattern if the UAE-side MDT process is delayed or if a particular complexity (high-titre anti-drug antibodies, advanced cardiac-renal disease, family-based research-registry enrolment) is better managed at KFSHRC. The home-emirate continuity-of-care plan stays the same; your UAE-side geneticist remains your primary clinician with surveillance visits scheduled around the cross-border infusion calendar.

The access pathway in the UAE: step by step

1. Diagnostic confirmation (enzyme assay plus GLA sequencing) on UAE soil; migalastat amenability check via international reference laboratory if not yet done. 2. Clinical geneticist or metabolic specialist consultation at SKMC, SSMC, Tawam, Cleveland Clinic Abu Dhabi, or Dubai Hospital with the documentation packet from Reserve Meds. 3. Baseline organ assessment: cardiac (echo, MRI), renal (eGFR, albuminuria), neurological, audiology, ophthalmology. 4. ERT choice decision with the treating geneticist (Elfabrio versus Replagal versus Fabrazyme versus migalastat where amenable). If switching from another ERT, antibody testing. 5. EDE named-patient filing through the hospital's import pharmacy with Reserve Meds providing the documentation packet. 6. First Elfabrio infusion at the qualified UAE centre under clinical geneticist or metabolic specialist supervision; pre-medication regimen titrated based on infusion-reaction history; anaphylaxis-management capability on site. 7. Stable every-2-week infusion routine established over the next 2 to 3 months; subsequent infusions can shorten in duration from approximately 3 hours to approximately 1.5 hours in patients tolerating the slower rate. 8. Ongoing surveillance: lyso-Gb3 and Gb3 biomarkers at intervals, anti-drug antibody titre at intervals, eGFR every 3 months, echocardiogram annually (or more often based on cardiac phenotype), neurological reassessment, family cascade testing follow-up.

The cost conversation, in the form a UAE family needs

The 2026 indicative annual list price of Elfabrio is approximately USD 350,000 to USD 400,000 per year for an average-weight adult at 1 mg/kg every-2-weeks dosing, or approximately AED 1.29 million to AED 1.47 million per year. Over a multi-decade therapy course, cumulative drug cost can sit between USD 10 million and USD 20 million, before counting cardiac valve replacement if disease progresses, dialysis or renal transplantation if renal disease progresses, and other supportive care.

When we issue a quote at intake, we separate every line: drug per infusion, infusion-suite charges, premedication, antibody and biomarker monitoring labs, cardiac and renal surveillance, our coordination fee. Nothing is bundled. We do not put a markup on the manufacturer's drug price. We charge a transparent coordination fee for the case-management work, disclosed in writing before any funds move.

Insurance coverage of Elfabrio in the UAE is uneven and the recent-FDA-approval status means many insurers are still building their internal pathway for it. Daman has approved Fabrazyme cases through prior authorisation for certain employer plans and for Thiqa-covered Emirati nationals; the Elfabrio pre-authorisation conversation is often a parallel-product conversation, with the geneticist's letter documenting why Elfabrio rather than Fabrazyme is the recommended choice. Private insurers vary widely. We supply your insurer with the documentation packet at no charge. We do not process the claim or guarantee coverage.

For Emirati nationals being treated at SKMC, SSMC, or Tawam under the public system, much of the cost may be underwritten through the government health funding pathways and the rare-disease desk at DoH Abu Dhabi has an established mechanism for adult LSD cases. Your treating consultant will confirm whether and how. For expatriate residents, the cost picture is typically a mix of insurance coverage, employer support where applicable, and family-pay.

What to monitor on Elfabrio

The surveillance schedule is built around the multisystemic nature of Fabry disease and around the known safety considerations of Elfabrio specifically:

- Lyso-Gb3 and Gb3 biomarkers at baseline and at intervals (typically 6 months) as biochemical efficacy markers. - Anti-drug antibody (IgG ADA) titre at intervals. ADAs develop in approximately 50 percent of Elfabrio patients; in most cases they do not affect efficacy, but persistent high-titre neutralising antibodies are monitored and may prompt clinical reassessment. - eGFR and albuminuria every 3 months. Urine protein/creatinine ratio at the same cadence. Renal stability is the primary efficacy endpoint of long-term ERT. - Echocardiogram annually, or more often based on cardiac phenotype. Strain imaging and LV mass tracking. Cardiac MRI with T1 mapping at intervals where available. - Neurological reassessment annually. Pain diary review. Brain MRI at intervals to monitor for silent infarcts and white matter progression. - Audiology and ophthalmology annually. - Infusion-associated reaction surveillance at every infusion. Most reactions are mild to moderate and respond to slowing the infusion and additional premedication; hypersensitivity and rare anaphylaxis remain on the differential and anaphylaxis-management capability is on site at every infusion. - Membranous glomerulonephritis surveillance through urine protein monitoring (this is a rare but documented Fabry-ERT class consideration).

Mental-health screening. Fabry disease carries a meaningful psychosocial burden. Chronic neuropathic pain, progressive cardiac and renal disease, the X-linked inheritance pattern with family-planning weight, and the diagnostic-delay journey many patients have walked all contribute. Depression and anxiety are documented at substantially elevated rates in Fabry cohorts versus the general population. PHQ-9 screening at baseline and at routine intervals is appropriate; C-SSRS screening where clinical concern arises. Psychiatry or clinical psychology referral should be a standing option in the multidisciplinary team structure, not a crisis-only afterthought. We surface this directly because it is under-attended in many adult-rare-disease care pathways.

Religious-ethical considerations

Elfabrio is produced in plant cell culture (tobacco, Nicotiana tabacum) and chemically modified with PEG. It is not derived from animal tissue and not derived from human plasma. The plant-cell origin is operationally simpler from a halal-kosher framing perspective than mammalian-cell products in some interpretations, though the Sunni and Shia bioethics consensus on disease-modifying therapies for life- and function-preserving indications is broadly permissive regardless of cell-line origin. Families typically consult with their religious advisors before committing; we will not pressure that conversation. We will provide the technical information about the production method when asked.

For Fabry families weighing the cascade-testing conversation for first-degree relatives, the genetic counselling team at your treating centre is the right home for that. The conversation often touches on family-planning, on screening of adult siblings and parents, and on whether children of an affected mother should be tested in childhood or after age 18. Reserve Meds coordinates the operational logistics; the clinical conversation stays with your team.

When Elfabrio is not the right answer, or not the only answer

For patients with an amenable GLA mutation, oral migalastat is the alternative to lifelong every-2-week IV ERT. The amenability testing should be done before the ERT conversation closes.

For patients who are stable on Replagal or Fabrazyme with good clinical and biomarker response and no antibody-related issues, switching to Elfabrio is not automatic; the treating geneticist makes the call based on patient-specific factors.

For patients with very advanced cardiac or renal disease at diagnosis, the conversation includes whether ERT will meaningfully alter the trajectory or whether supportive care (cardiac valve replacement, dialysis, renal transplantation) is the more meaningful intervention. Your geneticist and the cardiology and nephrology teams will frame this candidly. We will support whatever the family and the treating team decide.

For patients pursuing emerging gene-therapy programmes for Fabry disease, we can talk through trial eligibility and access where it applies, but we will not present trial therapy as routinely available.

What Reserve Meds does, and what we do not do

Reserve Meds is a US-based concierge coordinator for cross-border and complex specialty medicine. For a UAE adult pursuing Elfabrio, our scope is the diagnostic-confirmation pathway routing, the multidisciplinary team documentation packet, the EDE filing in collaboration with your treating hospital's import pharmacy, the sourcing logistics from Chiesi's authorised distribution through DSCSA-compliant chain of custody, cold-chain shipment to the qualified UAE centre (2 to 8 degrees Celsius, do not freeze), and named case-lead coordination from intake through the establishment of a stable every-2-week infusion routine. We continue to coordinate refills, documentation, antibody-monitoring scheduling, and any cross-border travel for second opinions at KFSHRC Riyadh or elsewhere.

Reserve Meds is not your prescriber. We do not practise medicine. We do not manufacture Elfabrio. We do not own or operate the infusion centre. We are not your insurer. Clinical decisions stay with your geneticist or metabolic specialist and the infusion centre team; we are the operational layer that turns those decisions into a coordinated case.

We work cash-pay where applicable. Our coordination fee is disclosed in writing. We will not start work without a signed engagement.

What to do if you want to start

The first concrete step is a call with our case-lead so we can confirm where you are in the diagnostic and clinical picture, and whether the right next move is the workup, the amenability check, the ERT choice conversation with your geneticist, or the EDE filing.

If you have been diagnosed with Fabry but have not yet seen a geneticist or metabolic specialist with Fabry-ERT experience, reach out anyway: we will help you align the MDT before any operational work begins.

Most patients reach us first on WhatsApp, which is the medium we hold open during UAE business hours and on weekends for active cases.

Start your treatment plan on the portal, or open a WhatsApp conversation with the case-lead and we will take it from there.

---

Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating geneticist or metabolic specialist and the infusion centre team.

Clinical and regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-05-20.